Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study von Gillis, R., Peled, N., Goldshtien, I., Rotem, O., Rozenblum, A.B., Nechushtan, H., Chen, L., Dudnik, E., Zer, A., Yust-Katz, S., Shelef, I., Roisman, L.C., Inbar, E.

Volltext